Last reviewed · How we verify
artificial tear therapy
Artificial tear therapy replaces or supplements the eye's natural tear film to lubricate the ocular surface and relieve symptoms of dry eye disease.
Artificial tear therapy replaces or supplements the eye's natural tear film to lubricate the ocular surface and relieve symptoms of dry eye disease. Used for Dry eye disease (keratoconjunctivitis sicca), Ocular surface irritation and discomfort.
At a glance
| Generic name | artificial tear therapy |
|---|---|
| Sponsor | Tianjin Medical University Eye Hospital |
| Drug class | Ophthalmic lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Artificial tears are topical ophthalmic solutions formulated to mimic the composition and function of natural tears, providing lubrication and protection to the cornea and conjunctiva. They help restore the tear film barrier, reduce friction during blinking, and alleviate discomfort associated with insufficient tear production or poor tear quality. The formulations typically contain water, electrolytes, and mucomimetic or viscosity-enhancing agents.
Approved indications
- Dry eye disease (keratoconjunctivitis sicca)
- Ocular surface irritation and discomfort
Common side effects
- Transient blurred vision
- Eye irritation or stinging
- Allergic reaction (rare)
Key clinical trials
- Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD (PHASE1)
- SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease (PHASE4)
- A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease (PHASE3)
- A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (PHASE2)
- FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial (PHASE3)
- Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure (PHASE1)
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (PHASE1, PHASE2)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- artificial tear therapy CI brief — competitive landscape report
- artificial tear therapy updates RSS · CI watch RSS
- Tianjin Medical University Eye Hospital portfolio CI